Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-09-18
2009-02-10
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
active
07488482
ABSTRACT:
A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5719054 (1998-02-01), Boursnell et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5866131 (1999-02-01), Ramshaw et al.
patent: 5866136 (1999-02-01), Ramshaw et al.
patent: 6096869 (2000-08-01), Stanley et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6884786 (2005-04-01), Kieny et al.
patent: 7118754 (2006-10-01), Balloul et al.
patent: WO 90/10459 (1990-09-01), None
patent: WO 92/16636 (1992-10-01), None
patent: WO 93/00436 (1993-01-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 94/23037 (1994-10-01), None
patent: WO 94/24267 (1994-10-01), None
patent: WO 96/00583 (1996-01-01), None
patent: WO 96/11274 (1996-04-01), None
patent: WO 96/29091 (1996-09-01), None
Zhou et al., Virology, 185:241-257, 1991.
Heck et al., PNAS USA, 89:4442-4446, 1992.
Galloway, 1994, “Human Papillomavirus Vaccines: A Warty Problem”, Infectious Agents and Disease, 3:187-193.
Hines et al., 1995, “Prospects for a Vaccine against Human Papillomavirus”, Obstectrics and Gynecology, 86(5):860-866.
Gajewski, 1996, “B7.1 but not B7.2 Efficiently Costimulates CD8+ T Lymphocytes in the P815 Tumor System in vitro”, The Journal of Immunology, 156:465-472.
Crook et al., “Degradation of P53 can be Targeted by HPV E6 Sequences Distinct from those Required for P53 Binding and Transactivation”, Cell, 1991, 67:547-556.
International Search Report dated Nov. 19, 1997.
Meyer et al. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Journal of General Virology. vol. 72, pp. 1031-1038.
Borysiewicz et al. The Lancet. Jun. 1, 1996; 347: 1523-1527.
Lin et al. (Virology. 1992; 187: 612-619.
Munger et al., 1989, “Complex Formation of Human Papillomavirus E7 Proteins with the Retinoblastoma Tumor Suppressor Gene Product”, The EMBO Journal, 8: 4099-4105.
Bubenik et al., International Journal of Oncology, Mar. 1996; 8: 477-481.
Baltz, American Journal of Health-System Pharmacy. 1995; 52: 2574-2585.
Hagensee et al., Journal of Virology, 1993; 67 (1): 315-322.
Bash et al., Journal of Immunotherapy. 1993; 14: 269-272.
Balloul Jean-Marc
Bizouarne Nadine
Kieny Marie-Paule
Buchanan Ingersoll & Rooney P.C.
Salimi Ali R.
Transgene S.A.
LandOfFree
Pharmaceutical compositions for treating papillomavirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for treating papillomavirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for treating papillomavirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093140